SEC Info - Amgen Inc - ‘S-3’ on 8/4/03

SEC Info℠

Home

My Interests

Help

Please Sign In

Amgen Inc – ‘S-3’ on 8/4/03 – EX-12.1

On: Monday, 8/4/03, at 5:08pm ET · Accession #: 1047469-3-26118 · File #: 333-107639

Previous ‘S-3’: ‘S-3/A’ on 10/23/02 · Next & Latest: ‘S-3/A’ on 10/7/03 · 15 References:

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/04/03  Amgen Inc                         S-3                    6:459K                                   Merrill Corp/New/FA

Registration Statement for Securities Offered Pursuant to a Transaction — Form S-3
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-3         Registration Statement for Securities Offered       HTML    184K 
                          Pursuant to a Transaction                              
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML    232K 
 3: EX-5.1      Opinion re: Legality                                HTML     33K 
 4: EX-12.1     Statement re: Computation of Ratios                 HTML     23K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML      8K 
 6: EX-25.1     Statement re: Eligibility of Trustee                HTML     34K

EX-12.1 — Statement re: Computation of Ratios
Exhibit Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) AMGEN INC. COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Dollars in Millions) QuickLinks
1	1st Page - Filing Submission
"	AMGEN INC. COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Dollars in Millions)
"	QuickLinks

This exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

QuickLinks -- Click here to rapidly navigate through this document

EXHIBIT 12.1

AMGEN INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Dollars in Millions)

			Six Months Ended June 30,						Year Ended December 31,
			2003			2002			2002			2001			2000		1999			1998
Earnings (loss):
	Income (loss) before income taxes		$	1,536.8		$	1,091.7		$	(684.5	)	$	1,686.3		$	1,674.3	$	1,566.2		$	1,224.4
	Fixed charges, less capitalized interest			24.3			25.2			59.0			23.9			24.4		23.1			16.5
	Equity in (earnings) losses of 50%-or less owned unconsolidated affiliates			(21.9	)		(14.4	)		(23.7	)		(16.1	)		7.8		(17.4	)		2.5

		Total earnings (loss)	$	1,539.2		$	1,102.5		$	(649.2	)	$	1,694.1		$	1,706.5	$	1,571.9		$	1,243.4

Fixed Charges:
	Interest expense, net		$	15.7		$	19.7		$	44.2		$	13.6		$	15.9	$	15.2		$	10.0
	Capitalized interest			12.6			3.5			8.1			12.7			12.3		11.6			19.2
	Portion of rents deemed to be interest			8.6			5.5			14.8			10.3			8.5		7.9			6.5

		Total fixed charges	$	36.9		$	28.7		$	67.1		$	36.6		$	36.7	$	34.7		$	35.7

Ratio of earnings to fixed charges				41.7			38.4			(a	)		46.3			46.5		45.3			34.8

(a): Earnings are approximately $716.3 million lower than the amount needed to cover fixed charges in this year, as earnings were impacted by a write-off of acquired in-process research and development of approximately $3.0 billon related to the acquisition of Immunex Corporation.

QuickLinks

AMGEN INC. COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Dollars in Millions)

Dates Referenced Herein and Documents Incorporated by Reference

This ‘S-3’ Filing	Date	Other Filings

	12/31/03	10-K, 11-K, 5
Filed on:	8/4/03	4
		List all Filings

15 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/03/24  Amgen Inc.                        10-Q        3/31/24   81:8.5M
 2/14/24  Amgen Inc.                        10-K       12/31/23  159:22M
10/31/23  Amgen Inc.                        10-Q        9/30/23   85:10M
 8/04/23  Amgen Inc.                        10-Q        6/30/23   86:10M
 4/28/23  Amgen Inc.                        10-Q        3/31/23   82:9.6M
 2/09/23  Amgen Inc.                        10-K       12/31/22  144:21M
11/04/22  Amgen Inc.                        10-Q        9/30/22   81:10M
 8/05/22  Amgen Inc.                        10-Q        6/30/22   82:12M
 4/28/22  Amgen Inc.                        10-Q        3/31/22   77:9M
 2/16/22  Amgen Inc.                        10-K       12/31/21  139:19M
11/03/21  Amgen Inc.                        10-Q        9/30/21   80:11M
 8/04/21  Amgen Inc.                        10-Q        6/30/21   79:11M
 4/28/21  Amgen Inc.                        10-Q        3/31/21   74:8.3M
 2/09/21  Amgen Inc.                        10-K       12/31/20  140:20M
10/29/20  Amgen Inc.                        10-Q        9/30/20   78:11M

↑Top

Filing Submission 0001047469-03-026118 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)